

To: (10)(2e) (10)(2e)@minvws.nl; (10)(2e) 20(2e) (10)(2e) (10)(2e) @minvws.nl]
From: (10)(2e) 010(2e)1C (10)(2e)
Sent: Mon 5/18/2020 8:42:52 PM
Subject: RE: Covid-19 test-strategy?
Received: Mon 5/18/2020 8:43:08 PM

Zeer vasthoudend iemand...nu al via 6 VWS'ers binnengekegen.

(10)(2e) (10)(2e)
(10)(2e)
(10)(2e) @minvws.nl
+31 (10)(2e)

-----Oorspronkelijk bericht-----

Van: (10)(2e) <(10)(2e)@minvws.nl>
Verzonden: maandag 18 mei 2020 22:30
Aan: (10)(2e) 010(2e)1C (10)(2e) <(10)(2e) @minvws.nl>; (10)(2e) 20(2e) (10)(2e) <(10)(2e) @minvws.nl>
Onderwerp: FW: Covid-19 test-strategy?

-----Oorspronkelijk bericht-----

Van: (10)(2e)@gllcmedical.com <(10)(2e)@gllcmedical.com>
Verzonden: zaterdag 16 mei 2020 10:20
Aan: (10)(2e) <(10)(2e)@minvws.nl>
Onderwerp: Covid-19 test-strategy?

Dear (10)(2e)

I am currently looking for the responsible team for your Covid-19 test-strategy planning, and hope you can kindly guide me in the right direction?

We have recently released a high quality, rapid test-kit for IgG and IgM antibodies against SARS-CoV-2 (Colloidal Gold-based) to be used by front-line healthcare professionals (nurses, doctors, etc.) to identify either whether a person has been infected and is now past the infection period, or if the person is currently infected with active virus, with high probability of the virus spreading and infecting others.

In collaboration with our ISO-certified kit-developer we have to date conducted more than 3,000 random tests combined with 300 controlled tests – both indicating an accuracy rate better than 99%. By late May we're expecting the first comprehensive, independent clinical study performed by Jinyintan Hospital in Wuhan, with the initial data-release indicating >94% sensitivity and >98% specificity.

In parallel, we are providing samples to a number of National Medicine Agencies and their microbiology/virology labs - in Europe, Asia and Africa, for additional independent performance validation. If there may be an interest in potentially adding a high quality and easy-to-use supplemental tool to your regional or national testing-arsenal in the long-term fight against SARS-CoV-2, I'll happily send you a number of samples (i.e. (10)(2e)) for your own testing, validation and comparison with existing or planned testing-methods.

Looking forward to hearing from you.

Rods
(10)(2e)

--
(10)(2e) (10)(2e) (PA)
GLLC-Medical Ltd
Hagenholzstrasse 83B
CH-8050 Zürich
E-mail: (10)(2e)@gllcmedical.com <(10)(2e)@gllcmedical.com>
Tel: (10)(2e)
Web: https://gllcmedical.com (10)(2e)
(10)(2e)
(10)(2e)